Faeth Therapeutics (FTH) Treasury Shares (2020 - 2026)

Faeth Therapeutics' (FTH) quarterly Treasury Shares came in at $24937.0 in Q1 2026, up 1067.46% on a QoQ basis from $2136.0 in Q4 2025.

Faeth Therapeutics (FTH) Treasury Shares (2020 - 2026) Analysis & Trends

Faeth Therapeutics (FTH) has 6 years of Treasury Shares data on file, last reported at $24937.0 in Q1 2026.

Quarterly Treasury Shares changed N/A year-over-year to $24937.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24937.0 (changed N/A YoY) and the FY2025 annual result came in at $2136.0, down 48.88% from the prior year.
Treasury Shares rose to $24937.0 in Q1 2026, from $2136.0 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $270162.0 in Q1 2023 to a low of $2136.0 in Q4 2025.
A 5-year average of $123259.9 and a median of $117187.0 in 2024 frame the typical range for Treasury Shares.
Annual changes were most pronounced in 2023 — Treasury Shares surged 31.66% — and 2025, when it slumped 98.29%.
Tracing FTH's Treasury Shares over 5 years: stood at $215854.0 in 2022, then slumped by 61.34% to $83441.0 in 2023, then plunged by 94.99% to $4178.0 in 2024, then tumbled by 48.88% to $2136.0 in 2025, then surged by 1067.46% to $24937.0 in 2026.
The last three Treasury Shares figures came in at $24937.0 (Q1 2026), $2136.0 (Q4 2025), and $2274.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn	-
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn	-
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	2.72 Mn
10	Faeth Therapeutics	185.89 Mn	185.89 Mn	-	502.00

Download Data